AUTHORS
Teresa Calmieri, MD, PhD, Mathilde Fekom, PhD2, Paolo Fiore, MD3, Patricia Lopez Pereira, MD4, Gerald Illerhaus, MD5, Christopher P. Fox, MD, PhD6, Elisabeth Schorb, MD7, Wolfgang Bethge, MD8, Christof Scheid, MD9, Gesine Bug, MD10, Thomas Erger, MD11, Deborah Richardson12, Christoph Schmid, MD13, Friedrich Stölzel14, Giulio Cassanello, MD15, Bertram Glass, MD16, Catherine Thieblemont, MD, PhD17, Anna Maria Sureda Balari, MD,PhD18, Andrés J.M. Ferreri, MD19, Ali Bazarbachi20
AFFILIATIONS
1 Strategic Program on Lymphomas, IRCCS San Raffaele Scientific Institute, Milan, Italy
2 European Society for Blood and Marrow Transplantation, Paris, France
3 Strategic Program on Lymphomas, IRCCS San Raffaele Scientific Institute, Milan, Italy
4 Clinical Hematology Department, Institut Català d’Oncologia-L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain
5 Klinikum Stuttgart, Stuttgart, Germany
6 Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
7 Department of Medicine I, Medical Centre – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
8 University Hospital Tuebingen; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, Tuebingen, Germany
9 University of Cologne, Cologne, Germany
10 University Hospital Frankfurt - Goethe University, Frankfurt Main, Germany
11 University Hospital | Linkoeping, Linkoeping, Sweden
12 Southampton General Hospital, Southampton, United Kingdom
13 Augsburg University Hospital, Augsburg, Germany
14 University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
15 Strategic Program on Lymphomas, IRCCS San Raffaele Scientific Institute, Milan, Italy
16 Department of Hematology, Oncology and Tumor Immunology, Helios Klinik Berlin-Buch, Berlin, Germany
17 15Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France
18 Clinical Hematology Department, Institut Català d’Oncologia-L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain
19 Strategic Program on Lymphomas, IRCCS San Raffaele Scientific Institute, Milan, Italy
20 Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
ABSTRACT
Introduction: Primary central nervous system lymphoma (PCNSL) predominantly affects older individuals (median age ~68 years in population-based studies), where age-related comorbidities and frailty complicate therapeutic management. While high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) is the established first-line standard for fit younger patients, evidence regarding its feasibility, safety, and long-term efficacy in patients aged ≥70 years remains limited, particularly in real-world settings. Here, we analyzed data from EBMT centers to address this knowledge gap.
Methods: Adult PCNSL patients (≥70 years) treated and receiving HDC-ASCT in first line (2010–2023) were identified in the EBMT registry. The primary endpoint was progression-free survival (PFS). Cox regression model was conducted to assess the impact of age, Karnofsky PS (KPS), induction drugs, disease status at ASCT, Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) and conditioning regimen (Busulfan vs. BCNU -based) on patient outcomes.
Results: A total of 167 patients (46% female, 54% male) met the inclusion criteria. Median age at HDC-ASCT was 72.5 years (70-83 years), 80 (52%) had a KPS<90 and 14 (9%) had a KPS<70. ASCT procedures increased over time, while remaining stable starting from 2019: 41 (25%; 2010-2019), 66 (39%, 2019-2021), and 60 (36%, 2021-2023). HCT-CI was 0 in 83 (50%) patients, 1-2 in 45 (27%) patients, and ≥3 in 37 (22%) patients. Induction included high-dose Methotrexate in 137 (85%) patients, high-dose cytarabine in 127 (78%) patients, thiotepa in 56 (35%), and rituximab in 148 (91%) patients. Conditioning was based on thiotepa in 160 (97%) patients being balanced between busulfan (82 patients; 49%) and BCNU (76 patients; 46%). At the time of ASCT, 56 (33.5%) patients were in CR, 91 (54.5%) in PR, 10 (6.0%) in PD, and 10 (6.0%) were missing. After a median follow-up of 3.6 years (IQR 3.2-4.1), the 2-year progression-free survival (PFS) and overall survival (OS) of the entire cohort were 64.6% (95% CI 55.5-72.3) and 73.1% (95% CI 65-79.6), respectively. The 2-year relapse incidence (RI) and non-relapse mortality (NRM) were 23.7% (95% CI 16.7–31.5) and 11.7% (95% CI 6.8–18.0), respectively. No significant differences in PFS or OS were observed based on age (≤75 vs >75 years): 2-year PFS was 66.1% (95% CI 55.6–74.6) vs 59.4% (95% CI 39.6–74.6) and 2-year OS was 74.3% (95% CI 65.2–81.4) vs 68.4% (95% CI 49.1–81.6). Partner drug in thiotepa-based conditioning (busulfan vs. BCNU) did not impact PFS, OS, RI, or NRM. In multivariable analysis, KPS<90 was the only factor significantly associated with worse outcomes, impacting PFS (HR 2.24, p=.02), OS (HR 2.06, p=.032), and RI (HR 2.88, p=.012). All other evaluated variables were not significantly associated with outcomes. Causes of death (n=57, 34%) included disease relapse/progression (n=26, 15.5%), treatment-related (n=6, 3.5%), other reasons (n=15, 9%), and missing data (n=10, 6%).
Conclusions: To the best of our knowledge, this EBMT registry analysis represents the largest international study evaluating first-line HDC-ASCT in elderly PCNSL patients. With the limitations of a registry study, current feasibility and efficacy data suggest that a potentially curative approach with thiotepa-conditioned ASCT should be proposed to PCNSL patients aged ≥70 years, with KPS ≥70, and at least PR after validated HD-MTX-based polychemotherapy. These findings provide a valuable benchmark for clinical decision-making in this increasingly common, vulnerable population.
DISCLOSURES
Teresa Calmieri, MD, PhD: Janssen-Cilag S.p.A - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)